AP-188
(N,N-Dimethyltryptamine / DMT)
N,N-Dimethyltryptamine (DMT) is being advanced by Algernon NeuroScience, a new, wholly owned private equity subsidiary of Algernon Pharmaceuticals. DMT is a known psychedelic compound that occurs naturally in many plant species and also in many animals, including humans. DMT has been shown to induce neuroplasticity in several key preclinical studies, and we are the first in the world to investigate the drug as a potential new treatment for stroke patients and people suffering traumatic brain injury (TBI).